Sales of the company’s copycat to J&J’s blockbuster reached $150 million in the first quarter, adding to a surge in revenue ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...

US biotech major Amgen (Nasdaq AMGN) late Thursday announced financial results for the first quarter of 2025, revealing that ...

Amgen Inc (AMGN) reports a robust 9% revenue increase driven by key brands, despite facing pricing pressures and strategic ...

Reliable dividend income from high-quality companies is a great option for investors seeking to ride out stock market ...

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 ...

Amgen also launched the first biosimilar version of Regeneron’s Eylea, Pavblu, in the fourth quarter of 2024, which generated sales of $99 million in the first quarter of 2025. Another key ...

The main contribution came from sales growth (+23% year–on-year ... revenue in 2025 in the range of $33.79-35.92 billion. In 2024, Amgen demonstrated EBITDA growth to $15.16 billion, which ...

Amgen AMGN is off to a strong start in 2025 with its first-quarter earnings as well as sales beating estimates. Particularly, ...

The Unified Patent Court (UPC) has quickly become an important forum for pharmaceutical and biotech patent disputes in Europe ...

Amgen is an innovative leader in an industry where its products will always be in high demand. Microsoft is navigating the ...

Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful ...